You are here

  • Home
  • Archive
  • Volume 12, Issue 4
  • Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer

Article info

Article menu

Download PDFPDF

Immunotherapy biomarkers
Original research
Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer

Authors

  • Liang Zheng Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School Of Medicine, Shanghai, China PubMed articlesGoogle scholar articles
  • Fang Hu Department of Thoracic Medical Oncology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Zhejiang, ChinaHangzhou Institute of Medicine (HlM), Chinese Academy of Sciences, Zhejiang, China PubMed articlesGoogle scholar articles
  • Lin Huang Department of Clinical Laboratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School Of Medicine, Shanghai, ChinaShanghai Institute of Thoracic Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School Of Medicine, Shanghai, China PubMed articlesGoogle scholar articles
  • Jun Lu Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School Of Medicine, Shanghai, China PubMed articlesGoogle scholar articles
  • Xiaohua Yang Central Laboratory, Shanghai Chest Hospital, Shanghai Jiao Tong University School Of Medicine, Shanghai, China PubMed articlesGoogle scholar articles
  • Jianlin Xu Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School Of Medicine, Shanghai, China PubMed articlesGoogle scholar articles
  • Shuyuan Wang Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School Of Medicine, Shanghai, China PubMed articlesGoogle scholar articles
  • Yinchen Shen Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School Of Medicine, Shanghai, China PubMed articlesGoogle scholar articles
  • Runbo Zhong Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School Of Medicine, Shanghai, China PubMed articlesGoogle scholar articles
  • Tianqing Chu Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School Of Medicine, Shanghai, China PubMed articlesGoogle scholar articles
  • Wei Zhang Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School Of Medicine, Shanghai, China PubMed articlesGoogle scholar articles
  • Ying Li Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School Of Medicine, Shanghai, China PubMed articlesGoogle scholar articles
  • Xiaoxuan Zheng Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School Of Medicine, Shanghai, China PubMed articlesGoogle scholar articles
  • Baohui Han Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School Of Medicine, Shanghai, China PubMed articlesGoogle scholar articles
  • Hua Zhong Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School Of Medicine, Shanghai, China PubMed articlesGoogle scholar articles
  • Wei Nie Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School Of Medicine, Shanghai, China PubMed articlesGoogle scholar articles
  • Xueyan Zhang Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School Of Medicine, Shanghai, China PubMed articlesGoogle scholar articles

Citation

Zheng L, Hu F, Huang L, et al
Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer
Journal for ImmunoTherapy of Cancer 2024;12:e008190. doi: 10.1136/jitc-2023-008190
Online issue publication 
April 18, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.